About Us

Treating, improving, and extending patients’ lives.

Our Vision

We are dedicated to treating, improving and extending patients’ lives by developing breakthrough products to prevent disease progression, improve outcomes and protect against organ damage in cardiorenal diseases.

Renibus’ first-in-class lead program, RBT-1 (SnPP / FeS), is a potent inducer of Nrf2, IL-10, and ferritin. RBT-1 is currently in Phase 2 development in cardiac surgery and will soon enter a Phase 3 registration study for its lead indication to reduce the risk of postoperative complications following cardiothoracic surgery.

RBT-2 (tetrahydrocurmin), is an antioxidant and anti-fibrotic drug that has been shown to reduce the risk of CKD progression in preclinical models.

RBT-3 (FeS), a novel, low molecular weight iron nanoparticle, is one component of RBT-1 and is targeted at reducing the risk of cisplatin-induced nephrotoxicity and will be in clinical development in 2023.

RBT-9 (SnPP), a potent anti-inflammatory and anti-oxidant, is in early-stage development for the progression of NASH.

Our Leadership Team

FrankStonebanks

Read Frank's Bio

Frank Stonebanks
Chairman and CEO
JeffKeyser

Read Jeff's Bio

D. Jeff Keyser, RPh, JD, PhD
President and Chief Operating Officer
BhupinderSingh

Read Bhupinder's Bio

Bhupinder Singh, MD
Chief Medical Officer
JamieDonadio

Read Jamie's Bio

Jamie A. Donadio
Chief Financial Officer

Board of Directors

Frank Stonebanks
Chairman
D. Jeff Keyser, RPh, JD, PhD
Secretary and Director
Henrik Rasmussen, MD, PhD
Director
Bhupinder Singh, MD
Director
Carlos Guillem, MBA, PhD
Director

Scientific Advisors

Alpesh Amin, MD, MBA, MACP, SFHM, FACC, FHFSA, FRCP (Lond)
Chair, Department of Medicine Professor of Medicine, Executive Director, Hospital Medicine. University of California, Irvine.
Rakesh Arora, BA, MD, PhD
Director – Perioperative and Cardiac Critical Care, Harrington Heart Vascular Institute, University Hospitals/Case Western Reserve University
Javed Butler, MD, MPH, MBA,
President of the Baylor Scott and White Research Institute. Senior Vice President for the Baylor Scott and White Health
Andre Lamy, MD, MSc
Cardiac Surgeon, Population Health Research Institute. McMaster University, Canada.
Kevin W. Lobdell, MD LTC, MC, USAR
Professor-System Director CV Surgical Quality, Education, & Research. Atrium Health – Sanger Heart & Vascular Institute.
Patrick T. Murray, MD, FASN, FRCPI, FJFICMI
Professor of Clinical Pharmacology at University College Dublin, Consultant Physician at the Mater Misericordiae. University Hospital, Dublin, Ireland.
Hamid Rabb, MD
Medical Director of the Johns Hopkins Kidney Transplant Program, Professor of Medicine. Johns Hopkins.
Andrew Shaw, MD, FRCA, FCCM, FFICM
Professor and Chair, Department of Intensive Care and Resuscitation, Cleveland Clinic.
Alexander Zarbock, MD, PhD
Professor of Anesthesiology and Intensive Care Medicine at the University of Münster and Chair of the Department of Anesthesiology, Intensive Care and Pain Medicine at the University Hospital Münster
Glenn M. Chertow, MD, MPH
Chief, Division of Nephrology, Stanford University School of Medicine
Norman S. Coplon Satellite Healthcare Professor in Medicine, Division of Nephrology, Stanford University School of Medicine

Laboratory of Basic
and Translational Research
Seattle, WA

Renibus’ translational lab, led by Dr. Richard Zager, keeps Renibus one step ahead of others in terms of innovating. This small, flexible and very efficient lab enables Renibus to get quick answers to important questions and explore new areas without the time and cost of outsourcing.

Richard A. Zager, MD
SVP Translational Research
Ali C.M. Johnson, MS
Staff Scientist